Healthy cash position. As at end-2025, Yancoal had gross cash of A$2bn, equivalent to ~25% of the current market cap. 2026 guidance introduced by YAL: (1) attributable saleable production: 36.5-40.5mn tonnes (-5% to +5% YoY); (2) operating cash cost (excluding royalties): A$90-98/t (-2% to +7% YoY); (3) capex: A$750-900mn (up 0%- 20% YoY). Key risks: (1) further decline in coal price; (2) elevated input cost; (3) extreme weather that affects production and delivery.. 机构：招银国际 研究员：Wayne Fung Yancoal's (YAL) n ...

Core Viewpoint - Oil prices experienced significant increases on Friday, marking their largest daily gains in over a week, driven by President Trump's indication that the opportunity for diplomatic resolution regarding Tehran's nuclear program may be diminishing [1] Group 1 - Oil prices surged following geopolitical tensions, highlighting the sensitivity of the oil market to political developments [1] - The increase in oil prices reflects market reactions to potential changes in diplomatic relations and their implications for oil supply [1]

Company Overview - Innoviva was originally formed to manage royalty revenues from products developed with and licensed to GSK [1] - The company has evolved to create and drive shareholder value through three main components [1] Revenue Streams - The first component is the royalty business from two respiratory assets, Breo and Anoro, generating $250 million in gross royalty revenue last year [1] - The second component is the Specialty Therapeutics business, which delivered almost $120 million in U.S. sales last year and is expected to generate at least $150 million this year [2]

Core Insights - Jade Biosciences is focused on developing best-in-class therapeutics for various autoimmune diseases [3] - The company has three programs developed in collaboration with Paragon Therapeutics, which specializes in high affinity binding monoclonal antibodies and half-life extension technology [3] Company Overview - Jade Biosciences aims to leverage high affinity binding and half-life extension technology to enhance therapeutic efficacy [4] - The dual benefits of this approach include more complete inhibition of targets throughout the dosing interval and reduced patient burden through extended dosing intervals [4]

Group 1 - The core issue involves an investigation into Mister Car Wash, Inc.'s board of directors and its controlling stockholder, Leonard Green & Partners, L.P., for potential breaches of fiduciary duties related to a proposed take-private sale [1] - The proposed transaction entails Leonard Green & Partners, L.P. acquiring Mister Car Wash for $7.00 per share in cash, with no requirement for a vote from minority stockholders [2] - Leonard Green & Partners, L.P. currently holds 67% of Mister Car Wash's common stock, indicating significant control over the company's decisions [2] Group 2 - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities litigation and has initiated this investigation to protect the rights of minority stockholders [1][4] - The firm has a strong track record, having recovered over $25 billion for clients and being recognized in various legal accolades [4]

Core Viewpoint - The article discusses how Google's IPO created optimal technical conditions for traders to evaluate new market debuts [1] Group 1 - Google's IPO is highlighted as a benchmark for assessing future IPOs due to its favorable market conditions [1] - The technical indicators from Google's IPO can serve as a model for traders to filter and identify potential investment opportunities in upcoming IPOs [1] - The article emphasizes the importance of analyzing technical conditions in the context of new market entries, using Google's IPO as a case study [1]

New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tokenization is no longer a future concept. It is the infrastructure upgrade that is reshaping global finance today. Trillions in real-world assets — real estate, private credit, funds, equities and more — are moving on-chain. Leading this shift is Securitize, the institutional-grade tokenization platform powering BlackRock’s BUIDL fund, partnering with major banks and asset managers, and executing landmark deals such as tokenized luxury resorts. In the first ...

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation for alleged misleading statements regarding its AI infrastructure strategy and its financial implications during the Class Period from June 12, 2025, to December 16, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Oracle's AI infrastructure strategy would lead to significant increases in capital expenditures without corresponding near-term revenue growth [5]. - It is alleged that Oracle's increased spending poses risks to its debt, credit rating, free cash flow, and project funding capabilities [5]. - The lawsuit asserts that the defendants' statements about Oracle's business and prospects were materially false and misleading, resulting in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Oracle common stock during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, highlighting its effectiveness in representing shareholder interests [4].

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to reinvent customer experiences [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, reshaping the global economy [2] - Major firms like PwC and McKinsey acknowledge that AI could unlock multi-trillion-dollar potential, supporting Musk's ambitious forecast [3] Industry Trends - The AI revolution is characterized by a powerful breakthrough that is redefining work, learning, and creativity, attracting significant interest from hedge funds and top investors [4] - A smaller, under-owned company is identified as holding the key to the AI revolution, suggesting potential investment opportunities [4][6] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for significant social impact [8] Investment Opportunities - There is a belief that investors may regret not owning certain stocks related to AI advancements in the near future [9] - A detailed report on a groundbreaking AI company is available, highlighting its technology and growth potential [10] - Subscription to a premium newsletter offers access to exclusive insights and stock picks related to the AI sector, emphasizing the urgency of capitalizing on these opportunities [12][13]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and regulatory challenges [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, suggesting confidence in FDA approval despite known concerns from the FDA regarding clinical evidence [5]. - The defendants allegedly communicated misleading information to investors about the likelihood of NDA approval, leading to investor damages when the truth was revealed [5].